Key result
Current IV therapies for AHFS improve hemodynamics but fail to demonstrate short-term clinical benefit.
Why the study?
Do current and investigational intravenous therapies improve hemodynamics and short-term clinical benefit in patients with acute heart failure syndromes?
Systematic Review
Do current and investigational intravenous therapies improve hemodynamics and short-term clinical benefit in patients with acute heart failure syndromes?
Current intravenous therapies for acute heart failure improve hemodynamics but lack consistent short-term clinical benefits, highlighting a need for novel therapeutic approaches.
Questions reliance on current IV therapies for clinical benefit in acute HF; extends evidence supporting novel agent development.
CONTEXT: Acute Heart Failure Syndromes (AHFS) is a common admission diagnosis associated with high mortality and hospital readmissions. Given the mixed results of recent clinical trials, the early management of AHFS remains controversial. OBJECTIVE: To review the recent evidence regarding current and investigational therapies for the early management of AHFS. DATA SOURCES: A systematic search of peer-reviewed publications was performed on MEDLINE and EMBASE from January 1990 to August 2006. The results of unpublished or ongoing trials were obtained from presentations at national and international meetings and pharmaceutical industry releases. Bibliographies from these references were also reviewed, as were additional articles identified by content experts. STUDY SELECTION AND DATA EXTRACTION: Criteria used for study selection were controlled study design, relevance to clinicians and validity based on venue of publication and power analysis. DATA SYNTHESIS: Although all current intravenous therapies for the early management of AHFS appear to improve hemodynamics, this may not always translate into short-term clinical benefit. CONCLUSION: The results of the trials conducted to date in AHFS have generally been disappointing. There is, therefore, an unmet need for new therapeutic approaches for the early management of AHFS that may improve the short-term and long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Luca et al. (2007) conducted a systematic review in Acute Heart Failure Syndromes (AHFS). Current and investigational intravenous therapies was evaluated on Hemodynamics and short-term clinical benefit. Current intravenous therapies for acute heart failure syndromes improve hemodynamics but generally fail to demonstrate short-term clinical benefit in trials to date.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: